2.5 mg semaglutide equivalent to tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Switching from Semaglutide to Tirzepetide

Predicted contraindications: personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pregnancy, and history of severe pancreatitis

Red-flag symptoms such as severe abdominal pain, persistent vomiting, or jaundice require immediate cessation and urgent medical attention

Possibly Ineffective Nerve Damage Due to Chemotherapy Acetyl-carnitine has shown promising effects against chemotherapy-induced nerve damage in smaller clinical trials [85, 86]

Patients considering oral tirzepatide RDT in Seattle receive a full provider consultation before any prescription is issued, ensuring the treatment plan is appropriate for their individual health history and goals